First in the World! Arbele’s CDH17xCD3 Bispecific Antibody Received Clinical Trial Phase I Ethics Approval in Australia
On March 31, 2022, the clinical trial application of ARB202 received ethics approval in Australia. ARB202 is an innovative bispecific antibody drug developed by AIM-HI Portfolio Company Arbele, a biotech company based in the Hong Kong Science and Technology Park.…